GlaxoSmithKline (GSK) Share Forecast & Price Target

Compare

1,141 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GSK Analyst Ratings

Hold

3 Buy

7 Hold

4 Sell

Based on 14 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GSK Stock 12 Month Forecast

Average Price Target

1,976.15p

▼(-4.81% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is 1,976.15p with a high forecast of 2,750.00p and a low forecast of 1,500.00p. The average price target represents a -4.81% change from the last price of 2,076.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1356":"1,356p","2751":"2,751p","1704.75":"1,704.8p","2053.5":"2,053.5p","2402.25":"2,402.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1976.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.98K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1356,1704.75,2053.5,2402.25,2751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2223.846153846154,2267.6923076923076,2311.5384615384614,2355.3846153846152,2399.230769230769,2443.076923076923,2486.923076923077,2530.769230769231,2574.6153846153848,2618.4615384615386,2662.3076923076924,2706.153846153846,{"y":2750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2164.3192307692307,2148.6384615384613,2132.9576923076925,2117.276923076923,2101.596153846154,2085.9153846153845,2070.2346153846156,2054.5538461538463,2038.873076923077,2023.1923076923078,2007.5115384615385,1991.8307692307694,{"y":1976.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2127.6923076923076,2075.3846153846152,2023.076923076923,1970.7692307692307,1918.4615384615386,1866.1538461538462,1813.8461538461538,1761.5384615384614,1709.2307692307693,1656.923076923077,1604.6153846153848,1552.3076923076924,{"y":1500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1409.239,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1411.642,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1405.876,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1475.122,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1373.507,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1357.949,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1423.411,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1643.684,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1750.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1785.714,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810.019,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1909.722,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2180,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,750p

Average Price Target1,976p

Lowest Price Target1,500p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

1,900p

Sell

-8.48%

Downside

Reiterated

03/04/26

GlaxoSmithKline (GSK) Gets a Sell from Barclays

Graham Parry

Citi

―

Hold

―

Reiterated

03/03/26

Citi Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Sarita Kapila

Morgan Stanley

1,600p→1,700p

Sell

-18.11%

Downside

Reiterated

03/02/26

GSK price target raised to 1,700 GBp from 1,600 GBp at Morgan StanleyGSK price target raised to 1,700 GBp from 1,600 GBp at Morgan Stanley

Zain Ebrahim

J.P. Morgan

1,700p

Sell

-18.11%

Downside

Reiterated

03/02/26

J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

Matthew Weston

UBS

1,940p

Hold

-6.55%

Downside

Reiterated

02/26/26

GlaxoSmithKline (GSK) Receives a Hold from UBS

Michael Leuchten

Jefferies

2,450p

Buy

18.02%

Upside

Reiterated

02/26/26

Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

1,900p

Hold

-8.48%

Downside

Reiterated

02/19/26

GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank

Kerry Holford

Berenberg Bank

1,660p→2,000p

Hold

-3.66%

Downside

Reiterated

02/17/26

Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

2,250p→2,750p

Buy

32.47%

Upside

Reiterated

02/11/26

Sachin Jain

Bank of America Securities

2,100p→2,350p

Hold

13.20%

Upside

Reiterated

02/09/26

Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold

David Evans

Kepler Capital

1,500p

Hold

-27.75%

Downside

Reiterated

02/04/26

Kepler Capital Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

2,300p

Buy

10.79%

Upside

Reiterated

02/04/26

GlaxoSmithKline (GSK) Gets a Buy from Shore Capital

Rajan Sharma

Goldman Sachs

1,700p

Hold

-18.11%

Downside

Reiterated

12/17/25

Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Rajesh Kumar

HSBC

1,200p→1,500p

Sell

-27.75%

Downside

Reiterated

12/10/25

GSK price target raised to 1,500 GBp from 1,200 GBp at HSBCGSK price target raised to 1,500 GBp from 1,200 GBp at HSBC

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

12/05/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

1,900p

Sell

-8.48%

Downside

Reiterated

03/04/26

GlaxoSmithKline (GSK) Gets a Sell from Barclays

Graham Parry

Citi

―

Hold

―

Reiterated

03/03/26

Citi Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Sarita Kapila

Morgan Stanley

1,600p→1,700p

Sell

-18.11%

Downside

Reiterated

03/02/26

GSK price target raised to 1,700 GBp from 1,600 GBp at Morgan StanleyGSK price target raised to 1,700 GBp from 1,600 GBp at Morgan Stanley

Zain Ebrahim

J.P. Morgan

1,700p

Sell

-18.11%

Downside

Reiterated

03/02/26

J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

Matthew Weston

UBS

1,940p

Hold

-6.55%

Downside

Reiterated

02/26/26

GlaxoSmithKline (GSK) Receives a Hold from UBS

Michael Leuchten

Jefferies

2,450p

Buy

18.02%

Upside

Reiterated

02/26/26

Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

1,900p

Hold

-8.48%

Downside

Reiterated

02/19/26

GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank

Kerry Holford

Berenberg Bank

1,660p→2,000p

Hold

-3.66%

Downside

Reiterated

02/17/26

Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

2,250p→2,750p

Buy

32.47%

Upside

Reiterated

02/11/26

Sachin Jain

Bank of America Securities

2,100p→2,350p

Hold

13.20%

Upside

Reiterated

02/09/26

Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold

David Evans

Kepler Capital

1,500p

Hold

-27.75%

Downside

Reiterated

02/04/26

Kepler Capital Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

2,300p

Buy

10.79%

Upside

Reiterated

02/04/26

GlaxoSmithKline (GSK) Gets a Buy from Shore Capital

Rajan Sharma

Goldman Sachs

1,700p

Hold

-18.11%

Downside

Reiterated

12/17/25

Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

Rajesh Kumar

HSBC

1,200p→1,500p

Sell

-27.75%

Downside

Reiterated

12/10/25

GSK price target raised to 1,500 GBp from 1,200 GBp at HSBCGSK price target raised to 1,500 GBp from 1,200 GBp at HSBC

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

12/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+6.19%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +6.19% per trade.

1 Year

Justin SmithBernstein

Success Rate

8/10 ratings generated profit

Average Return

+20.79%

reiterated a buy rating 24 days ago

Copying Justin Smith's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +20.79% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+34.62%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +34.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GSK has received 12 Buy Ratings, 21 Hold Ratings, and 15 Sell Ratings. GSK average Analyst price target in the past 3 months is 1,976.15.

Each month's total comprises the sum of three months' worth of ratings.

GSK Financial Forecast

GSK Earnings Forecast

Next quarter’s earnings estimate for GSK is 0.43p with a range of 0.41p to 0.46p. The previous quarter’s EPS was 0.26p. GSK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Sales Forecast

Next quarter’s sales forecast for GSK is 7.66B with a range of 7.59B to 7.76B. The previous quarter’s sales results were 8.62B. GSK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Stock Forecast FAQ

What is GB:GSK’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 1,976.15.

What is GB:GSK’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:GSK, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GlaxoSmithKline a Buy, Sell or Hold?

GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 7 hold ratings and 4 sell ratings.

What is GlaxoSmithKline’s share price target?

The average share price target for GlaxoSmithKline is 1,976.15. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,750.00p ,and the lowest forecast is 1,500.00p. The average share price target represents -4.81% Decrease from the current price of 2,076p.

What do analysts say about GlaxoSmithKline?

GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of GlaxoSmithKline?

To buy shares of GB:GSK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

GlaxoSmithKline (GSK) Share Forecast & Price Target

GSK Analyst Ratings

GSK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GSK Analyst Recommendation Trends

GSK Financial Forecast

GSK Earnings Forecast

GSK Sales Forecast

GSK Stock Forecast FAQ

Detailed List of Analyst Forecasts